A previous study by Wu et al. demonstrated that hsa_circ_0001427 downregulation contributed to enzalutamide resistance, while Cao et al. showed that a circRNA derived from the AR was overexpressed when prostate cancer progressed to CRPC and could be detected in plasma [28,42]. The gene discussed is AR; the disease is prostate cancer.